Recent items - Alzheimer's & Dementia
A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers
29/04/2013 15:39
Abstract: Background: We aimed to develop a prediction model based on cerebrospinal fluid (CSF) biomarkers, that would yield a single estimate representing the probability that dementia in a memory clinic patient is due to Alzheimer’s disease (AD).
29/04/2013 15:39
Abstract: Background: We aimed to develop a prediction model based on cerebrospinal fluid (CSF) biomarkers, that would yield a single estimate representing the probability that dementia in a memory clinic patient is due to Alzheimer’s disease (AD).
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
29/04/2013 15:39
Abstract: Background: Clinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD.Met
29/04/2013 15:39
Abstract: Background: Clinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD.Met
Standardization of analysis sets for reporting results from ADNI MRI data
29/04/2013 15:39
Abstract: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) three-dimensional T1-weighted magnetic resonance imaging (MRI) acquisitions provide a rich data set for developing and testing analysis techniques for extracting structural endpoints.
29/04/2013 15:39
Abstract: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) three-dimensional T1-weighted magnetic resonance imaging (MRI) acquisitions provide a rich data set for developing and testing analysis techniques for extracting structural endpoints.
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
29/04/2013 15:39
Abstract: Background: Randomized controlled trials (RCTs) provide safety and efficacy data for regulatory approval of antidementia drugs, but offer limited data regarding real-world effectiveness. Long-term observational controlled studies (LTOCs) ex
29/04/2013 15:39
Abstract: Background: Randomized controlled trials (RCTs) provide safety and efficacy data for regulatory approval of antidementia drugs, but offer limited data regarding real-world effectiveness. Long-term observational controlled studies (LTOCs) ex
Predictors and outcomes for caregivers of people with mild cognitive impairment: A systematic literature review
29/04/2013 15:39
Abstract: Background: Dementia caregiving is strongly linked to depression, anxiety, and burden in caregivers. Little is known about whether the same holds for people supporting an older person with mild cognitive impairment (MCI). We aim to systemat
29/04/2013 15:39
Abstract: Background: Dementia caregiving is strongly linked to depression, anxiety, and burden in caregivers. Little is known about whether the same holds for people supporting an older person with mild cognitive impairment (MCI). We aim to systemat
Risk disclosure and preclinical Alzheimer’s disease clinical trial enrollment
29/04/2013 15:39
Abstract: To identify the facilitators and barriers to preclinical Alzheimer’s disease (AD) clinical trial recruitment, 50 cognitively normal participants were interviewed after being randomized to one of two hypothetical AD risk scenarios: (1) the
29/04/2013 15:39
Abstract: To identify the facilitators and barriers to preclinical Alzheimer’s disease (AD) clinical trial recruitment, 50 cognitively normal participants were interviewed after being randomized to one of two hypothetical AD risk scenarios: (1) the
Alzheimer's Association Update
29/04/2013 15:39
In April, the administration of U.S. President Barack Obama announced that the President's 2014 budget includes $100 million dedicated to the fight against Alzheimer's and the implementation of the National Plan to Address Alzheimer's Disease. The ne
29/04/2013 15:39
In April, the administration of U.S. President Barack Obama announced that the President's 2014 budget includes $100 million dedicated to the fight against Alzheimer's and the implementation of the National Plan to Address Alzheimer's Disease. The ne
Cognitive and functional resilience despite molecular evidence of Alzheimer’s disease pathology
29/04/2013 15:39
Abstract: Background: The correlation between neuropathological lesions and cognition is modest. Some individuals remain cognitively intact despite the presence of significant Alzheimer’s disease (AD) pathology, whereas others manifest cognitive sy
29/04/2013 15:39
Abstract: Background: The correlation between neuropathological lesions and cognition is modest. Some individuals remain cognitively intact despite the presence of significant Alzheimer’s disease (AD) pathology, whereas others manifest cognitive sy
Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia
29/04/2013 15:39
Abstract: Background: Although recent diagnostic criteria for Alzheimer's disease propose the use of biomarkers, validation of these biomarkers by diagnostic test accuracy studies is a necessary first step, followed by the synthesis of the evidence f
29/04/2013 15:39
Abstract: Background: Although recent diagnostic criteria for Alzheimer's disease propose the use of biomarkers, validation of these biomarkers by diagnostic test accuracy studies is a necessary first step, followed by the synthesis of the evidence f
Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease-Magnetic Resonance study
29/04/2013 15:39
Abstract: Background: Homocysteine may be a modifiable risk factor for cognitive decline and brain atrophy, particularly in older persons. We examined whether homocysteine increased the risk for cognitive decline and brain atrophy, and evaluated the
29/04/2013 15:39
Abstract: Background: Homocysteine may be a modifiable risk factor for cognitive decline and brain atrophy, particularly in older persons. We examined whether homocysteine increased the risk for cognitive decline and brain atrophy, and evaluated the
Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study
29/04/2013 15:39
Abstract: Background: Mild cognitive impairment (MCI) is associated with an increased dementia risk. This study reports incidence of MCI subtypes, rates of progression to dementia, and stability of MCI classification.Methods: We examined 873 communit
29/04/2013 15:39
Abstract: Background: Mild cognitive impairment (MCI) is associated with an increased dementia risk. This study reports incidence of MCI subtypes, rates of progression to dementia, and stability of MCI classification.Methods: We examined 873 communit
Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline
29/04/2013 15:39
Abstract: Background: Depressive symptoms in nondemented individuals appear to hasten the progression from mild cognitive impairment to clinical Alzheimer's disease (AD) and double the risk of incident AD. However, the mechanism(s) by which depressio
29/04/2013 15:39
Abstract: Background: Depressive symptoms in nondemented individuals appear to hasten the progression from mild cognitive impairment to clinical Alzheimer's disease (AD) and double the risk of incident AD. However, the mechanism(s) by which depressio
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease
29/04/2013 15:39
Abstract: Background: Reliable blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) phenotypic biomarkers of Alzheimer’s disease (AD) or mild cognitive impairment (MCI) are likely to emerge only from a systematic, quanti
29/04/2013 15:39
Abstract: Background: Reliable blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) phenotypic biomarkers of Alzheimer’s disease (AD) or mild cognitive impairment (MCI) are likely to emerge only from a systematic, quanti
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease
29/04/2013 15:39
Abstract: Objective: To evaluate the contributions of amyloid-positive (Am+) and medial temporal atrophy–positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer’s disease (AD).Methods: 18F-flutemetamol-labeled a
29/04/2013 15:39
Abstract: Objective: To evaluate the contributions of amyloid-positive (Am+) and medial temporal atrophy–positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer’s disease (AD).Methods: 18F-flutemetamol-labeled a
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study
29/04/2013 15:39
Abstract: Background: Multiplex assays such as xMAP have been proposed for the assessment of Alzheimer’s disease (AD) biomarkers amyloid β 42 (Aβ42), tau (Tau), and phosphorylated tau (pTau) in cerebrospinal fluid (CSF). Here, we compared the tra
29/04/2013 15:39
Abstract: Background: Multiplex assays such as xMAP have been proposed for the assessment of Alzheimer’s disease (AD) biomarkers amyloid β 42 (Aβ42), tau (Tau), and phosphorylated tau (pTau) in cerebrospinal fluid (CSF). Here, we compared the tra
Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia
29/04/2013 15:39
Abstract: Objective: In this study we investigated the relationships between cerebrospinal fluid (CSF) biomarkers (tau and amyloid-β1-42 [Aβ1-42]) and cognition or behavior in patients with frontotemporal dementia (the behavioral variant, bvFTD).Me
29/04/2013 15:39
Abstract: Objective: In this study we investigated the relationships between cerebrospinal fluid (CSF) biomarkers (tau and amyloid-β1-42 [Aβ1-42]) and cognition or behavior in patients with frontotemporal dementia (the behavioral variant, bvFTD).Me
CSF biomarker variability in the Alzheimer's Association quality control program
29/04/2013 15:39
Abstract: Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker
29/04/2013 15:39
Abstract: Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker
2013 Alzheimer's disease facts and figures
19/03/2013 01:18
Abstract: This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and soc
19/03/2013 01:18
Abstract: This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and soc
Alzheimer's Association Update
19/03/2013 01:18
Maria C. Carrillo, PhD, is the Alzheimer's Association's new vice president for medical and scientific relations. Carrillo, who joined the Association in 2005 as director of science grants, succeeds William Thies, PhD, who had led the Association's D
19/03/2013 01:18
Maria C. Carrillo, PhD, is the Alzheimer's Association's new vice president for medical and scientific relations. Carrillo, who joined the Association in 2005 as director of science grants, succeeds William Thies, PhD, who had led the Association's D
Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype
19/03/2013 01:18
Abstract: Retrospective data are presented to support a spectrum of early Alzheimer’s disease (AD) along a continuum defined by gender and genotype. The putative neurodegenerative mechanisms driving distinct phenotypes at each end of the spectrum a
19/03/2013 01:18
Abstract: Retrospective data are presented to support a spectrum of early Alzheimer’s disease (AD) along a continuum defined by gender and genotype. The putative neurodegenerative mechanisms driving distinct phenotypes at each end of the spectrum a
Current knowledge and future directions about the disclosure of dementia: A systematic review of the first decade of the 21st century
19/03/2013 01:18
Abstract: Background: The disclosure of Alzheimer's disease presents a great challenge because it entails emotionally charged communication about a life-threatening, incurable, and stigmatized disease. Although a broad consensus has evolved regarding
19/03/2013 01:18
Abstract: Background: The disclosure of Alzheimer's disease presents a great challenge because it entails emotionally charged communication about a life-threatening, incurable, and stigmatized disease. Although a broad consensus has evolved regarding
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
19/03/2013 01:18
Abstract: Background: Soluble oligomers of amyloid ß-protein (Aß) have been increasingly linked to synaptic dysfunction, tau alteration, and neuritic dystrophy in Alzheimer's disease (AD) and mouse models. There is a great need for assays that quan
19/03/2013 01:18
Abstract: Background: Soluble oligomers of amyloid ß-protein (Aß) have been increasingly linked to synaptic dysfunction, tau alteration, and neuritic dystrophy in Alzheimer's disease (AD) and mouse models. There is a great need for assays that quan
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging
19/03/2013 01:18
Abstract: Background: Frailty is a clinical syndrome generally associated with a greater risk for adverse outcomes such as falls, disability, institutionalization, and death. Cognition and dementia have already been considered as components of frailt
19/03/2013 01:18
Abstract: Background: Frailty is a clinical syndrome generally associated with a greater risk for adverse outcomes such as falls, disability, institutionalization, and death. Cognition and dementia have already been considered as components of frailt
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
19/03/2013 01:18
Abstract: Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possib
19/03/2013 01:18
Abstract: Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possib
TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial
19/03/2013 01:18
Abstract: A number of recent studies have not replicated the association of the translocase of the outer mitochondrial membrane pore subunit (TOMM40) rs10524523 polymorphism, which is in linkage disequilibrium with apolipoprotein E (APOE), with age o
19/03/2013 01:18
Abstract: A number of recent studies have not replicated the association of the translocase of the outer mitochondrial membrane pore subunit (TOMM40) rs10524523 polymorphism, which is in linkage disequilibrium with apolipoprotein E (APOE), with age o
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium
19/03/2013 01:18
Abstract: Recognizing that international collaboration is critical for the acceleration of biomarker standardization efforts and the efficient development of improved diagnosis and therapy, the Alzheimer's Association created the Global Biomarkers St
19/03/2013 01:18
Abstract: Recognizing that international collaboration is critical for the acceleration of biomarker standardization efforts and the efficient development of improved diagnosis and therapy, the Alzheimer's Association created the Global Biomarkers St
Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting
19/03/2013 01:18
Abstract: The Patient Protection and Affordable Care Act added a new Medicare benefit, the Annual Wellness Visit (AWV), effective January 1, 2011. The AWV requires an assessment to detect cognitive impairment. The Centers for Medicare and Medicaid Se
19/03/2013 01:18
Abstract: The Patient Protection and Affordable Care Act added a new Medicare benefit, the Annual Wellness Visit (AWV), effective January 1, 2011. The AWV requires an assessment to detect cognitive impairment. The Centers for Medicare and Medicaid Se
Improving dementia care: The role of screening and detection of cognitive impairment
19/03/2013 01:18
Abstract: The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking abo
19/03/2013 01:18
Abstract: The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking abo
Research and standardization in Alzheimer's trials: Reaching international consensus
19/03/2013 01:18
Abstract: Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from precli
19/03/2013 01:18
Abstract: Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from precli
Intracerebral propagation of Alzheimer’s disease: Strengthening evidence of a herpes simplex virus etiology
19/03/2013 01:18
Abstract: Background: A faulty human protein, abnormally phosphorylated tau, was recently publicized to spread “like a virus” from neuron to neuron in Alzheimer’s patients’ brains. For several decades, we have been amassing arguments showing
19/03/2013 01:18
Abstract: Background: A faulty human protein, abnormally phosphorylated tau, was recently publicized to spread “like a virus” from neuron to neuron in Alzheimer’s patients’ brains. For several decades, we have been amassing arguments showing
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
19/03/2013 01:18
Abstract: Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has iden
19/03/2013 01:18
Abstract: Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has iden
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
19/03/2013 01:18
Abstract: Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that su
19/03/2013 01:18
Abstract: Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that su
Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study
19/03/2013 01:18
Abstract: Background: The goal of this study was to examine cross-sectional and longitudinal associations between cognitive performance and beta amyloid (Aβ) load determined by florbetapir F18 positron emission tomography (PET) in nondemented oldest
19/03/2013 01:18
Abstract: Background: The goal of this study was to examine cross-sectional and longitudinal associations between cognitive performance and beta amyloid (Aβ) load determined by florbetapir F18 positron emission tomography (PET) in nondemented oldest
Predictors of progression to severe Alzheimer’s disease in an incidence sample
19/03/2013 01:18
Abstract: Background: Little is known about factors influencing time to severe Alzheimer’s disease (AD).Methods: Incident cases of AD in the Cache County Memory Study were identified. Severe AD was defined as Mini-Mental State Examination score of
19/03/2013 01:18
Abstract: Background: Little is known about factors influencing time to severe Alzheimer’s disease (AD).Methods: Incident cases of AD in the Cache County Memory Study were identified. Severe AD was defined as Mini-Mental State Examination score of